STAT+: Pharmalittle: Are new ADHD treatments really any better? India moves to reduce dependence on China for pharma ingredients
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Category: STAT+
STAT+: Nkarta studies of engineered natural killer cells show complete remissions in patients with blood cancers
Nkarta said Monday that two experimental, off-the-shelf treatments, both made from engineered natural killer cells,…
STAT+: There’s a new crop of treatments for ADHD in kids. Are they any better?
Parents and doctors now have more tools than ever before to help kids manage symptoms…
STAT+: Travel nurses remain pricey, and it’s weighing on hospital profits
An underwhelming first quarter at the country’s biggest hospital chain shows the pandemic’s stranglehold on…
STAT+: Pharmalittle: U.S. health agency workers fail to report political interference; Canada walks back some drug-pricing reforms
And so, another working week will soon draw to a close. Not a moment too…
STAT+: With milestones on the horizon, Guardant Health CEOs lay out their vision for cancer detection
SAN DIEGO — Bay Area biotech Guardant Health is closer than ever to its ultimate…
A new nonprofit wants to rewrite the playbook for how the U.S. government funds science
WASHINGTON — The Good Science Project is hoping to push the NIH and other government…
STAT+: CDC, FDA, and NIH staffers aren’t reporting political interference, new watchdog report shows
WASHINGTON — Staff at the nation’s health agencies suspect political interference is inappropriately influencing government…
STAT+: Pharmalittle: U.S. spending on medicines rose 12% last year; Louisiana sues a PBM for allegedly overcharging
Top of the morning to you. And a fine one it is. Blue skies and…
STAT+: U.S. spending on pharmaceuticals jumped 12% in 2021, fueled by costs of Covid-19 vaccines and therapies
Thanks to Covid-19 vaccines and therapies, U.S. spending on pharmaceuticals rose 12% in 2021 as…
Opinion: STAT+: Pharma’s role in value-based care starts with value-based research
Modern medicine has been sculpted by the ever-expanding knowledge of biological processes in conjunction with…
STAT+: Endo wins a reprieve in an opioid lawsuit in Tennessee as appeals court overturns sanctions
Endo International won a key battle over its role in the opioid crisis in Tennessee…
STAT+: Louisiana accuses UnitedHealth and its OptumRx PBM of inflating drug costs for its Medicaid program
In the latest bid to pull back the curtain on pharmacy benefit managers, the Louisiana…
STAT+: Pfizer faces criticism for arguing that intellectual property for its Covid-19 pill is a human right
Numerous advocacy groups and institutional shareholders are chiding Pfizer for arguing that its intellectual property…
STAT+: Pharmalittle: Glaxo workers in the U.K. vote to strike; Alabama reaches $276 million deal over opioid crisis
Hello, everyone, and welcome to the middle of the week. You made it this far,…
STAT+: What counts as a breakthrough? 8 insights on the FDA’s approach to medical devices
The word breakthrough carries a kind of weight: It’s a dramatic step forward, a critical…
STAT+: What Regeneron’s purchase of Checkmate Pharma says about the state of biotech
There are a few angles through which to view Tuesday’s acquisition of Checkmate Pharmaceuticals by…
STAT+: Pharmalittle: Global demand for Pfizer Covid-19 pill falls; biotech hub in Massachusetts set for a correction
Rise and shine, everyone, a busy day is on the way. We can tell thanks…
STAT+: In nation’s biotech hub, layoffs, closures, and mergers expected as part of an industry ‘correction’
Based on the unrelenting demand for more lab space in the Boston area, a boom…
STAT+: Animal rights group urges USDA to probe research facilities for failing to inspect monkey shipments
A prominent animal rights group asked U.S. authorities to investigate leading medical research labs for…
STAT+: Nation’s top cancer hospitals slap hefty markups on drugs, study says
The nation’s preeminent cancer hospitals are charging commercial health insurers anywhere from double to seven…
STAT+: Pharmalittle: U.K watchdog agency is urged to bolster conflicts policy; FDA device program helps makers more than patients
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Cel-Sci’s CEO used private call to tip off select investors about cancer drug update
Geert Kersten, the CEO of drugmaker Cel-Sci, stopped communicating publicly soon after the company’s cancer…
STAT+: Breakthrough Device Tracker: An authoritative database of FDA’s fast-tracked medical devices
The world of medical devices is growing more sprawling every day. Some promising novel ideas…
STAT+: FDA’s breakthrough device program, meant to benefit patients, is delivering the biggest gains for companies
Five years ago, the Food and Drug Administration launched a new program with the best…
STAT+: Pharmalittle: WTO head says Covid vaccine IP talks are nearing agreement; RSV is the next big target for vaccine makers
And so, another working will soon draw to a close. Not a moment too soon,…
STAT+: Bristol Myers agrees to settle lawsuit alleging anti-competitive deals involving HIV drugs
After three years of squabbling, Bristol Myers Squibb has agreed to pay up to $11…
STAT+: Omicron’s speedy retreat helped bolster UnitedHealth Group’s bottom line
The relative brevity of the Omicron surge helped the bottom line at UnitedHealth Group. UnitedHealth’s…
STAT+: Editas Medicine names new CEO — its fourth — as delays, poor data hamper its gene-editing treatments
Editas Medicine announced the hiring of a new CEO on Thursday — the fourth top…
STAT+: Pharmalittle: Justice Department probes Bausch over marketing; Pfizer to seek Covid booster for healthy 5- to 11-year-olds
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: ‘Completely unsustainable’: Small employers brace for giant health insurance price hikes
Many small companies are expected to face double-digit hikes to their health insurance premiums next…
STAT+: Hospitals have been financially propping up medical schools, but now it’s squeezing their bottom lines
Before Banner Health agreed to shore up a pair of financially struggling medical schools, leaders…
STAT+: Justice Department probes Bausch Health over marketing for dermatology drugs
Bausch Health is being investigated by U.S. authorities in connection with marketing of four medicines…
STAT+: Halozyme to acquire Antares for nearly $1B in bid to dominate drug delivery market
San Diego biotech Halozyme announced Wednesday that it plans to buy drug development and delivery…
STAT+: Pharmalittle: U.K. advances novel payment system for antibiotics; Glaxo to pay $1.9 billion for Sierra Oncology
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: Good fortunes continue for Sierra Oncology with $1.9 billion acquisition by U.K. pharma giant Glaxo
Sierra Oncology is having a very good year. On Wednesday, the small U.S. drugmaker said…
STAT+: Trying not one, but a three-drug combination to help engineered T cells fight cancer
NEW ORLEANS — For years, Kristin Anderson has been trying to push immunotherapy to work…
Opinion: STAT+: Incentives to spur repurposing of existing generics for novel uses would open a new paradigm in drug R&D
The Drug Price Competition and Patent Term Restoration Act of 1984, better known as the…
STAT+: Pharma pledges faster drug launches in Europe in hopes of avoiding stricter regulations
In a bid to thwart stricter regulation, the European pharmaceutical industry trade group pledged to…
STAT+: U.K. readies a Netflix-style subscription payment model for badly needed antibiotics
Amid rising concern over antimicrobial resistance, the U.K. has taken a major step toward becoming…
STAT+: Pharmalittle: Will Biogen sue CMS over Alzheimer’s drug coverage? Novartis plans to lay off thousands
Hello, everyone, and how are you this morning? A spot of rain is falling on…
STAT+: Will Biogen sue Medicare over its restrictions on the Alzheimer’s drug, Aduhelm? And other big legal questions about the decision
WASHINGTON — Biogen and other drugmakers have already hinted they might sue Medicare over its…
STAT+: New bipartisan insulin policy aims to entice drugmakers to lower prices
WASHINGTON — A bipartisan group of four key lawmakers unveiled a long-shot policy that aims…
STAT+: FDA scolds Bausch Health for misleading claims about a psoriasis cream
The U.S. Food and Drug Administration has scolded Bausch Health for a video and webpage…
STAT+: Giving immunotherapy before surgery prevents lung cancer from returning, study says
Giving the immunotherapy Opdivo, made by Bristol-Myers Squibb, to lung cancer patients before surgery can…
STAT+: Pharmalittle: Lilly and Eisai will still seek accelerated approval for Alzheimer’s drugs; CAR-T cells may shrink some solid tumors
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Private equity giant Carlyle to acquire biotech venture capital firm Abingworth
The Carlyle Group will acquire Abingworth, one of biotech’s oldest venture capital groups, it announced…
STAT+: Natural killer cells, primed with an antibody, induce remissions in patients with advanced lymphoma
An experimental immunotherapy involving so-called natural killer cells elicited complete remissions in a majority of…
STAT+: Lighting up cancer cells with pH-activated nanoparticles
On a screen at the American Association of Cancer Research (AACR) conference on Saturday, one…
STAT+: ‘Precedents are important’: Aduhelm coverage restrictions could shape the future of accelerated approval
Whither accelerated approval? Amid the hubbub over new Medicare coverage restrictions for Alzheimer’s treatments, a…